BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32253601)

  • 1. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy.
    Nagata Y; Kato K; Miyamoto T; Hirano H; Shoji H; Iwasa S; Honma Y; Takashima A; Hamaguchi T; Matsushita H; Nagashima K; Saruta M; Boku N
    Support Care Cancer; 2020 Dec; 28(12):5861-5869. PubMed ID: 32253601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
    Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
    Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
    Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
    Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
    Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.
    Maeda O; Ando T; Ishiguro K; Watanabe O; Miyahara R; Nakamura M; Funasaka K; Kazuhiro F; Ando Y; Goto H
    Mol Clin Oncol; 2014 Nov; 2(6):1103-1106. PubMed ID: 25279205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.
    Hisakane K; Ohmatsu H; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Goto K
    J Nippon Med Sch; 2017; 84(5):231-236. PubMed ID: 29142184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.
    Yokomichi N; Imai K; Sakamoto M; Horiki M; Yamauchi T; Miwa S; Inoue S; Uneno Y; Suzuki H; Wada T; Ichikawa Y; Morita T
    BMC Cancer; 2022 Feb; 22(1):218. PubMed ID: 35227250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites.
    Ito T; Hanafusa N; Iwase S; Noiri E; Nangaku M; Nakagawa K; Miyagawa K
    Int J Clin Oncol; 2015 Jun; 20(3):623-8. PubMed ID: 25239690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites.
    Ohashi A; Nakai S; Yamada S; Kato M; Hasegawa M
    Ther Apher Dial; 2019 Jun; 23(3):242-247. PubMed ID: 31033167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Kim Y; Ajiki T; Ueda Y; Yoshida Y; Takahashi T; Fukuyama H; Fukuyama T; Hori Y
    Anticancer Res; 2024 Feb; 44(2):613-619. PubMed ID: 38307557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study.
    Yamamoto K; Nagao S; Tsu T; Matsushima T; Ishido Y; Narita M; Suzuki K; Nakazawa H; Shibutani T; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    J Obstet Gynaecol Res; 2021 Apr; 47(4):1536-1543. PubMed ID: 33469981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
    Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.
    Ito T; Hanafusa N; Fukui M; Yamamoto H; Watanabe Y; Noiri E; Iwase S; Miyagawa K; Fujita T; Nangaku M
    Ther Apher Dial; 2014 Feb; 18(1):87-92. PubMed ID: 24499089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two Cases of Peritoneal Dissemination of Gastric Cancer Treated with CART Followed by Chemotherapy].
    Kitagawa Y; Katsuno A; Tamura N; Harada T; Abe S; Hamasaki S; Machida T; Nakanishi A; Ami K; Umetani N
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):1887-1889. PubMed ID: 33468862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
    Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
    PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital].
    Iwaki R; Shindo K; Kawahara H; Nanba N; Kuramoto Y; Beppu T; Uesugi T; Tanaka Y; Uesugi Y
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2165-2167. PubMed ID: 30692319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
    Kawata Y; Nagasaka K; Matsumoto Y; Oda K; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Arimoto T; Osuga Y; Fujii T
    Int J Clin Oncol; 2019 Apr; 24(4):420-427. PubMed ID: 30474762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.